GlassScriptPhysician profile
Arnold I Pallay
NPI 1538105960
$9,818.82
in general payments reported to CMS, 2019-2025
47 companies · $723 in 2025
The $723 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $467 · 2021: $929 · 2022: $893 · 2023: $2,941 · 2024: $3,463 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,070 · Food and Beverage: $2,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,070.00 |
| Food and Beverage | $2,057.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $5,280.79 | 2020-2025 | |
| Novo Nordisk INC | $731.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $468.26 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $369.86 | 2021-2025 | |
| Pfizer INC. | $357.06 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $353.59 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Glaxosmithkline, LLC. | $294.37 | 2019-2025 | Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.44 | 2020-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Alexion Pharmaceuticals, INC. | $215.28 | 2023-2025 | Strensiq |
| Lilly USA, LLC | $204.29 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $126.24 | 2019-2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $105.80 | 2019-2025 | Breztri |
| Exact Sciences Corporation | $90.38 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $88.46 | 2021-2022 | |
| Allergan, INC. | $85.24 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Pallay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.